Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy.
McKelvey BA, Garrett-Mayer E, Rivera DR, Alabaster A, Andrews HS, Bond EG, Brown TD, Bruno A, Damato L, Espirito JL, Fernandes LL, Hansen E, Kluetz P, Ma X, McCracken A, Mishra-Kalyani PS, Natanzon Y, Potter D, Robert NJ, Schwartz L, Schwind R, Sweetnam C, Wagner J, Stewart MD, Allen JD. McKelvey BA, et al. Among authors: kluetz p. JCO Clin Cancer Inform. 2024 Aug;8:e2400091. doi: 10.1200/CCI.24.00091. JCO Clin Cancer Inform. 2024. PMID: 39146509 Free PMC article.
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice.
Liu L, Choi J, Musoro JZ, Sauerbrei W, Amdal CD, Alanya A, Barbachano Y, Cappelleri JC, Falk RS, Fiero MH, Regnault A, Reijneveld JC, Sandin R, Thomassen D, Roychoudhury S, Goetghebeur E, le Cessie S; SISAQOL-IMI Work Package 3. Liu L, et al. Lancet Oncol. 2023 May;24(5):e197-e206. doi: 10.1016/S1470-2045(23)00110-9. Lancet Oncol. 2023. PMID: 37142381 Review.
Successes and Challenges of PARP Inhibitors in Cancer Therapy.
Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R. Ricks TK, et al. Among authors: kluetz p. Front Oncol. 2015 Oct 14;5:222. doi: 10.3389/fonc.2015.00222. eCollection 2015. Front Oncol. 2015. PMID: 26528434 Free PMC article. Review. No abstract available.
Global Variation in Opioid Use in Prostate Cancer Trials.
Roydhouse JK, Suzman DL, Menapace LA, Mishra-Kalyani PS, Sridhara R, Blumenthal GM, Beaver JA, Pazdur R, Kluetz PG. Roydhouse JK, et al. JAMA Oncol. 2019 Nov 1;5(11):e192971. doi: 10.1001/jamaoncol.2019.2971. Epub 2019 Nov 14. JAMA Oncol. 2019. PMID: 31513232 Free PMC article.
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X, Qiu J, Fan J, Song P, Yu J, Zhang X, King-Kallimanis BL, Chen W, Ricks TK, Gong Y, Wang X, Windsor K, Rhieu SY, Geiser G, Banerjee A, Chen X, Reyes Turcu F, Chatterjee DK, Pathak A, Seidman J, Ghosh S, Philip R, Goldberg KB, Kluetz PG, Tang S, Amiri-Kordestani L, Theoret MR, Pazdur R, Beaver JA. Narayan P, et al. Among authors: kluetz pg. Clin Cancer Res. 2021 Apr 1;27(7):1842-1849. doi: 10.1158/1078-0432.CCR-20-3652. Epub 2020 Nov 9. Clin Cancer Res. 2021. PMID: 33168657 Free PMC article. Clinical Trial.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group.
Magnuson A, Bruinooge SS, Singh H, Wilner KD, Jalal S, Lichtman SM, Kluetz PG, Lyman GH, Klepin HD, Fleury ME, Hirsch B, Melemed A, Arnaldez FI, Basu Roy U, Schenkel C, Sherwood S, Garrett-Mayer E. Magnuson A, et al. Clin Cancer Res. 2021 May 1;27(9):2424-2429. doi: 10.1158/1078-0432.CCR-20-3868. Epub 2021 Feb 9. Clin Cancer Res. 2021. PMID: 33563633 Free PMC article. Review.
172 results